Lometrexol disodium

Synonyms: DDATHF disodium
Lometrexol (DDATHF) disodium 是一种抗嘌呤类抗叶酸 (antifolate) 药,可抑制甘氨酰胺核糖核苷酸甲酰基转移酶 (GARFT) 的活性而不引起可检测水平的 DNA 链断裂,并通过进一步抑制嘌呤从头合成导致异常的细胞增殖、凋亡 (apoptosis) 和细胞周期停滞,具有抗癌活性,同时还是一种有效的人丝氨酸羟甲基转移酶 1/2 (hSHMT1/2) 抑制剂。
产品编号: MS-Q27689 纯度: 98.0% CAS No.: 120408-07-3 分子式: C21H23N5Na2O6 分子量: 487.42
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in Water
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价

产品描述

Lometrexol (DDATHF) disodium 是一种抗嘌呤类抗叶酸 (antifolate) 药,可抑制甘氨酰胺核糖核苷酸甲酰基转移酶 (GARFT) 的活性而不引起可检测水平的 DNA 链断裂,并通过进一步抑制嘌呤从头合成导致异常的细胞增殖、凋亡 (apoptosis) 和细胞周期停滞,具有抗癌活性,同时还是一种有效的人丝氨酸羟甲基转移酶 1/2 (hSHMT1/2) 抑制剂。

生物实验数据

生物活性 Lometrexol (DDATHF) disodium is an antipurine antifolate that inhibits glycinamide ribonucleotide formyltransferase (GARFT) activity without causing detectable levels of DNA strand breaks, and by further inhibiting de novo purine synthesis, it leads to aberrant cell proliferation, apoptosis, and cell cycle arrest; it exhibits anticancer activity and is also a potent inhibitor of human serine hydroxymethyltransferase 1/2 (hSHMT1/2).
体外研究
(In Vitro)

Lometrexol (DDATHF) disodium binds tightly to GART, resulting in a rapid and prolonged depletion of intracellular purine ribonucleotides.
Lometrexol (1-30 μM; 2-10 hours) disodium induces rapid and complete growth inhibition in L1210 cells.
Lometrexol (1 μM; 2-24 hours) disodium induces cell cycle arrest in murine leukemia L1210 cells.

Cell Viability Assay

Cell Line: Mouse leukemia L1210 cells
Concentration: 1, 30 μM
Incubation Time: 2, 4, 6, 8, 10 hours
Result: Induced rapid and complete growth inhibition.

Cell Cycle Analysis

Cell Line: L1210 cells
Concentration: 1 μM
Incubation Time: 2, 4, 8, 12, 24 hours
Result: Caused a rapid loss of the G2/M phase population of cells and an early S phase accumulation of cells by 8 hours. By 24 h, the S phase population appeared to be slowly shifting to higher DNA content, and hence, from mid-to-late S phase.
体内研究
(In Vivo)

Lometrexol (DDATHF; i.p.; 15-60 mg/kg; on gestation day 7.5) disodium induces neural tube defects (NTDs) by disturbing purine metabolism and increases the rate of embryonic resorption and growth retardation in a dose-dependent manner.
Lometrexol (i.p.; 40 mg/kg; on gestation day 7.5) disodium decreases glycinamide ribonucleotide formyl transferase (GARFT) activity and Changes of ATP, GTP, dATP and dGTP levels.
Lometrexol (i.p.; 40 mg/kg; on gestation day 7.5) disodium induces abnormal proliferation and apoptosis exist in neural tube defects (NTDs).

Animal Model: C57BL/6 mice (7-8 week, 18-20 g)
Dosage: 15, 30, 35, 40, 45 and 60 mg/kg
Administration: Intraperitoneal injection; on gestation day 7.5
Result: Increased the rate of embryonic resorption and growth retardation in a dose-dependent manner.
Animal Model: C57BL/6 mice (7-8 week, 18-20 g)
Dosage: 40 mg/kg
Administration: Intraperitoneal injection; on gestation day 7.5, for 0, 6, 24, 48 and 96 hours
Result: Inhibited glycinamide ribonucleotide formyl transferase (GARFT) activity and GARFT activity was maximally inhibited after at 6 hours.
Decreased the levels of ATP, GTP, dATP, and dGTP of NTDs embryonic brain tissue significantly at 6 hours.
Animal Model: C57BL/6 mice (7-8 week, 18-20 g)
Dosage: 40 mg/kg
Administration: Intraperitoneal injection; on gestation day 7.5, for 4 days
Result: Decreased the expression of proliferation-related genes (Pcna, Foxg1 and Ptch1) and increased the expression of apoptosis-related genes (Bax, Casp8 and Casp9) in NTD groups.
性状 固体
颜色 White to light yellow

化学信息

分子量 487.42
分子式 C21H23N5Na2O6
CAS No. 120408-07-3
别名 DDATHF disodium

储存&溶解度

储存方式

-20°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : 100 mg/mL (205.16 mM; 超声助溶)

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O1 mM2.0516 mL10.2581 mL20.5162 mL51.2905 mL
5 mM0.4103 mL2.0516 mL4.1032 mL10.2581 mL
10 mM0.2052 mL1.0258 mL2.0516 mL5.1290 mL
15 mM0.1368 mL0.6839 mL1.3677 mL3.4194 mL
20 mM0.1026 mL0.5129 mL1.0258 mL2.5645 mL
25 mM0.0821 mL0.4103 mL0.8206 mL2.0516 mL
30 mM0.0684 mL0.3419 mL0.6839 mL1.7097 mL
40 mM0.0513 mL0.2565 mL0.5129 mL1.2823 mL
50 mM0.0410 mL0.2052 mL0.4103 mL1.0258 mL
60 mM0.0342 mL0.1710 mL0.3419 mL0.8548 mL
80 mM0.0256 mL0.1282 mL0.2565 mL0.6411 mL
100 mM0.0205 mL0.1026 mL0.2052 mL0.5129 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础